Akero Therapeutics, Inc. (AKRO) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	10-K
Revenues	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]	29.9	19.1	15.2	8.6	1.9
General and administrative	29.9	19.1	15.2	8.6	1.9
Research and development	85.3	81.8	64.9	37.0	11.9
EBITDA [+]	-115.1	-100.8	-80.1
EBITDA growth	14.1%	25.8%	75.5%	231.3%
Depreciation and amortization	0.0	0.0	0.0
EBIT [+]	-115.2	-100.9	-80.2	-45.7	-13.8
EBIT growth	14.1%	25.9%	75.6%	231.3%
Interest expense	0.7
Interest expense	0.7
Other income (expense), net [+]	3.9	0.1	0.9	1.9	-67.9
Other non-operating income	3.9	0.1	0.9	1.9
Other non-ooperating expenses					0.0
Other	-3.9	0.1	0.9	1.9	-67.9
Pre-tax income	-112.0	-100.8	-79.2	-43.7	-81.7
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%		0.0%
Net income	-112.0	-100.8	-79.2	-43.8	-82.2

Basic EPS [+]	($2.87)	($2.89)	($2.52)	($2.90)	($795.28)
Growth	-0.7%	14.9%	-13.3%	-99.6%
Diluted EPS [+]	($2.87)	($2.89)	($2.52)	($2.90)	($795.28)
Growth	-0.7%	14.9%	-13.3%	-99.6%


Shares outstanding (basic) [+]	39.0	34.8	31.5	15.1	0.1
Growth	11.9%	10.7%	108.8%	14474.7%
Shares outstanding (diluted) [+]	39.0	34.8	31.5	15.1	0.1
Growth	11.9%	10.7%	108.8%	14474.7%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.